Abstracts tagged "Abatacept and rheumatoid arthritis (RA)"

Abstract Number: 2490 • 2014 ACR/ARHP Annual Meeting
Assessment of Structural Benefits of SC Abatacept Using MRI in Patients with RA Who Have Failed 1 or 2 TNFs and Correlated with Clinical Outcomes As Measured By DAS28(ESR)
Norman B. Gaylis¹, Steven Needell² and Joanne Sagliani³, ¹Arthritis & Rheumatic Disease Specialties, Aventura, FL, ²Boca Radiology, Boca Raton, FL, ³Research, Arthritis & Rheumatic Disease Specialties, Aventura, FL
Background/Purpose: Previous studies1-2 suggest the structural benefit of IV abatacept in patients with RA who have previously failed MTX, TNF therapy or both. Objectives:This study…
Abstract Number: 1517 • 2014 ACR/ARHP Annual Meeting
Analysis of Gene Expression Fluctuation with Abatacept Highlights the Involvement of the Proteasome Pathway As a Mechanism of Action of Abatacept in Rheumatoid Arthritis
C Derambure¹, O Vittecoq^1,2, G Dzangue Tchoupou¹, Maria-Antonietta d'Agostino³, P Gaudin⁴, C Gaillez⁵, M Le Bars⁶ and T Lequerré^1,2, ¹Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ²Department of Rheumatology, Rouen University Hospital, Rouen, France, ³AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, ⁴Department of Rheumatology, University Hospital Grenoble, Grenoble, France, ⁵Formerly of Bristol-Myers Squibb, Rueil-Malmaison, France, ⁶Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: Abatacept (ABA) is a biologic therapy targeting T cells, which play a major role in the pathophysiology of RA. Overall, 57.1% of patients reached…
Abstract Number: 430 • 2013 ACR/ARHP Annual Meeting
Comparing abatacept to Adalimumab, Etanercept and Infliximab As First Or Second Line Agents in Patients With Rheumatoid arthritis: Experience From the rhumadata® Clinical Database and Registry
Denis Choquette¹, Diane Sauvageau², Louis Bessette³, Boulos Haraoui^4,5, Jean Pierre Pelletier¹, Jean-Pierre Raynauld², Edith Villeneuve² and Louis Coupal¹, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ³Centre Hospitalier Universitaire de Québec, pavillon CHUL, Sainte-Foy, QC, Canada, ⁴Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁵Rhumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada
Background/Purpose: The order of use of biologic agents is still a question for debate. Phase III trial data in MTX-IR patients show comparable efficacy results…
Abstract Number: 1485 • 2013 ACR/ARHP Annual Meeting
RNA Transcripts From Peripheral Blood Mononuclear Cells As Predictors Of Clinical Responsiveness In Rheumatoid Arthritis Subjects Treated With Abatacept
Matthew Henkel¹, Fang Du², Donald M. Jones³, Erich R Wilkerson², William Horne⁴, Jay K. Kolls⁵, Marc C. Levesque⁶ and Mandy McGeachy¹, ¹Medicine, Univeristy of Pittsburgh, Pittsburgh, PA, ²Medicine, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴Pediatrics, University of Pittsburgh, Pittsburgh, PA, ⁵Richard King Mellon Foundation Institute for Pediatric Research, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ⁶Division of Rheumatology and Clinical Immunology, University of Pittsburgh Department of Medicine, Pittsburgh, PA
Background/Purpose: Biologics, including abatacept (CTLA4Ig), improve outcomes for many RA patients. However, approximately 40-50% of RA patients fail to respond to abatacept, and there are…
Abstract Number: 1421 • 2013 ACR/ARHP Annual Meeting
Treatment Responses and Their Predictors Of Abatacept In Biologic naïve Patients With Rheumatoid Arthritis; Data Form Abroad Study
Yutaka Kawahito¹, Takao Fujii², Akira Yokota³, Hideo Hashimoto⁴, Kiyoshi Matsui⁵, Kenji Miki⁶, Masayasu Kitano⁵, Naoki Shinmyo⁷, Aihiro Yamamoto¹, Koichiro Ohmura⁸, Takanori Kuroiwa⁹, Toshihiko Hidaka¹⁰, Ichiro Yoshii¹¹, Hideko Nakahara¹², Takashi Fujimoto¹³, Kosaku Murakami¹⁴, Satoshi Morita¹⁵, Masahiro Sekiguchi⁵, Norihiro Nishimoto^16,17, Tsuneyo Mimori⁸ and Hajime Sano⁵, ¹Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ²Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ³Yokota Clinic for Rheumatology, Osaka, Japan, ⁴Dept of Orthopedic Surgery, Rinku Hashimoto Rheumatology Orthopaedics, Osaka, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan, ⁶Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ⁷Kashiba Asahigaoka Hospital, Kashiba, Japan, ⁸Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁹Department of Rheumatology, Yukioka Hospital, Osaka, Japan, ¹⁰Zenjinkai Shimin-No-Mori Hospital, Miyazaki, Japan, ¹¹Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹²Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ¹³Nara Medical University, Kashihara, Japan, ¹⁴Rheumatology and Clinical Immunology, Osaka Red Cross Hospital, Osaka, Japan, ¹⁵Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, ¹⁶Tokyo Medical University, Tokyo, Japan, ¹⁷Osaka Rheumatology Clinic, Osaka, Japan
Background/Purpose: The identification of predictors of good response to biologic therapy is needed in the perspective of personalized medicine.　To determine the predicting factors of efficacy…
Abstract Number: 1415 • 2013 ACR/ARHP Annual Meeting
Safety and Effectiveness Of Abatacept In 3985 Japanese Patients With Rheumatoid Arthritis; Japan All-Cases Post-Marketing Surveillance
Takao Koike¹, Masayoshi Harigai², Naoki Ishiguro³, Shigeko Inokuma⁴, Junnosuke Ryu⁵, Syuji Takei⁶, Tsutomu Takeuchi⁷, Y. Tanaka⁸, Masahiko Watanabe⁹ and Hisashi Yamanaka¹⁰, ¹Rheumatology, NTT Sapporo Medical Center, Sapporo, Japan, ²Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Department of Allergy and Rheumatology diseases, Japanese Red Cross Medical Center, Tokyo, Japan, ⁵Nihon University School of Medicine, Tokyo, Japan, ⁶School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ⁷Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Bristol-Myers K.K, Tokyo, Japan, ¹⁰Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: A large-scale post-marketing surveillance (PMS) has been implemented to evaluate the safety and effectiveness on the use of intravenous abatacept (ABT) in Japanese patients…
Abstract Number: 2547 • 2012 ACR/ARHP Annual Meeting
Weekly Subcutaneous Abatacept Confers Comparable Onset of Treatment Response and Magnitude of Efficacy Improvement Over 6 Months When Administered with or without an Intravenous Abatacept Loading Dose
M. Schiff¹, R. Alten², M. Weinblatt³, P. Nash⁴, Roy Fleischmann⁵, P. Durez⁶, J. Kaine⁷, I. Delaet⁸, S. Kelly⁸, M. Maldonado⁸, S. Patel⁸ and M. C. Genovese⁹, ¹University of Colorado, Denver, CO, ²Schlosspark-Klinik, University Medicine, Berlin, Germany, ³Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ⁴University of Queensland, Brisbane, Australia, ⁵University of Texas Southwestern Medical Center, Dallas, TX, ⁶Université Catholique de Louvain, Brussels, Belgium, ⁷Sarasota Arthritis Research Center, Sarasota, FL, ⁸Bristol-Myers Squibb, Princeton, NJ, ⁹Stanford University, Palo Alto, CA
Background/Purpose: To compare clinical and functional responses with SC abatacept administered with or without an IV loading dose, in pts with active RA and inadequate…
Abstract Number: 2314 • 2012 ACR/ARHP Annual Meeting
Correlation Between Abatacept and Rheumatoid Factor – Can Rheumatoid Factor Be a Predictive Factor for Abatacept?
Tomonori Kobayakawa¹, Masatoshi Hayashi², Toshihisa Kanamono², Atsushi Kaneko³, Toshihisa Kojima⁴ and Naoki Ishiguro⁵, ¹Orthopedic Surgery, Nagoya university, Nagoya, Japan, ²Departments of Orthopedic surgery and Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, ³Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, ⁴Orthopedic Surgery and Rheumatology, Nagoya Univeristy, School of Medicine, Nagoya, Japan, ⁵Department of Orthopedic Surgery, Nagoya University, Graduate School & Faculty of Medicine, Nagoya, Aichi, Japan
Background/Purpose: Abatacept (ABT), a T-cell selective costimulatory regulator, went on the market in Japan in September 2010, with a number of reports issued on its…
Abstract Number: 2159 • 2012 ACR/ARHP Annual Meeting
Correlation of a Multi-Biomarker Disease Activity Response Assessment to Disease Activity Score 28 (C-Reactive Protein) Response Assessment and Omeract Ramris Scores in a Placebo-Controlled Rheumatoid Arthritis Clinical Trial with Abatacept (ASSET)
DJ Haney¹, G. Cavet², P. Durez³, R. Alten⁴, Gerd Burmester⁵, P. P. Tak⁶, Anca Catrina⁷, C. Gaillez⁸, M. Le Bars⁸, S. Connolly⁹ and R. Townsend⁹, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Crescendo Bioscience, Inc., South San Francisco, CA, ³Université Catholique de Louvain, Brussels, Belgium, ⁴Schlosspark-Klinik, University Medicine, Berlin, Germany, ⁵Charité-Universitätsmedizin, Berlin, Germany, ⁶Academic Medical Center/University of Amsterdam, Amsterdam, the Netherlands; GlaxoSmithKline, Stevenage, United Kingdom, ⁷Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁸Bristol-Myers Squibb, Rueil Malmaison, France, ⁹Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: A novel multi-biomarker disease activity (MBDA) score has been validated and is a tool for monitoring disease activity in RA.1 Here, we evaluate the…
Abstract Number: 1289 • 2012 ACR/ARHP Annual Meeting
Abatacept Biologic-Free Remission Study in Established Rheumatoid Arthritis Patients. Orion Study
Tsutomu Takeuchi¹, Tsukasa Matsubara², Shuji Ohta³, Masaya Mukai⁴, Koichi Amano⁵, Shigeto Tohma⁶, Yoshiya Tanaka⁷, Hisashi Yamanaka⁸ and Nobuyuki Miyasaka⁹, ¹Keio University School of Medicine, Tokyo, Japan, ²Matsubara Mayflower Hospital, Hyogo, Japan, ³Department of Rheumatology, Taga General Hospital, Ibaraki, Japan, ⁴Dept Rheumatology & Hematology, Sapporo City General Hospital, Sapporo, Japan, ⁵Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Saitama, Japan, ⁶Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, ⁷The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁸Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁹Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Abatacept (ABA) has comparable efficacy to TNF inhibitors in achieving clinical remission in rheumatoid arthritis (RA) patients. However, although clinical evidence suggests that biologic-free…
Abstract Number: 356 • 2012 ACR/ARHP Annual Meeting
Safety of Abatacept in Rheumatoid Arthritis with Chronic Hepatitis B VIRUS Infection
Melissa Padovan¹, Elisabetta Lanciano², Oscar Epis³, Alessandro Mathieu⁴, Giulia Erba⁵, Leopoldo Ciani⁶, Sarah Giacuzzo¹ and Marcello Govoni⁷, ¹Department if Clinical and Experimental Medicine, University of Ferrara, Section of Rheumatology, Ferrara, Italy, ²Section of Internal Medicine, Policlinico Universitario di Bari, Rheumatology Unit, Bari, Italy, ³Ospedale Niguarda Cà Granda, Rheumatology Unit, Milano, Italy, ⁴Medical Sciences, University of Cagliari, Rheumatology Unit, Cagliari, Italy, ⁵AO San Gerardo, Medical Clinics, Monza, Italy, ⁶Ospedale Civile di Legnano, Unit of Internal Medicine, Legnano, Italy, ⁷Department of Clinical and Experimental Medicine, Section of Rheumatology, Ferrara, Italy
Background/Purpose: In patients with rheumatoid arthritis (RA) concomitant hepatitis B (HBV) represents a therapeutic challenge limiting, DMARD treatment options (conventional and biologics, especially anti-TNFa and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].